On August 10, Tempus AI rose 5.1% in regular trading, trading at $54.76/share, with turnover of $42.24 million.

The stock continues to gain following the company's Q2 earnings report, which significantly exceeded market expectations. Tempus AI reported a Q2 adjusted loss of $0.04 per share, far narrower than the analyst consensus estimate of a $0.14 loss, representing an 81.82% improvement over the $0.22 loss from the prior year. Revenue for the quarter reached $382.5 million, up from $314.6 million a year earlier, beating the $379.7 million consensus. The company also raised its full-year revenue guidance to $1.60 billion to $1.61 billion, above the FactSet estimate of $1.59 billion.

Additionally, Tempus AI previously announced its approximately $1.5 billion enterprise-value acquisition of cancer detection company Personalis, integrating molecular residual disease testing into its AI-driven precision oncology platform, further expanding its business scope and reinforcing its competitive positioning in the healthcare AI space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)